WO2003047519A3 - 'compressed annular tablet with molded triturate tablet for oral and intraoral' - Google Patents

'compressed annular tablet with molded triturate tablet for oral and intraoral' Download PDF

Info

Publication number
WO2003047519A3
WO2003047519A3 PCT/US2002/038246 US0238246W WO03047519A3 WO 2003047519 A3 WO2003047519 A3 WO 2003047519A3 US 0238246 W US0238246 W US 0238246W WO 03047519 A3 WO03047519 A3 WO 03047519A3
Authority
WO
WIPO (PCT)
Prior art keywords
tablet
intraoral
oral
patient
dosage form
Prior art date
Application number
PCT/US2002/038246
Other languages
French (fr)
Other versions
WO2003047519A2 (en
Inventor
Jane Hirsh
Kamal Midha
Mark Hirsh
Whe-Yong Lo
Original Assignee
Peirce Man Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peirce Man Llc filed Critical Peirce Man Llc
Priority to CA002468558A priority Critical patent/CA2468558A1/en
Priority to EP02789933A priority patent/EP1455759A2/en
Priority to AU2002352973A priority patent/AU2002352973B2/en
Priority to JP2003548780A priority patent/JP2005511647A/en
Publication of WO2003047519A2 publication Critical patent/WO2003047519A2/en
Publication of WO2003047519A3 publication Critical patent/WO2003047519A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

New pharmaceutical compositions in unit dosage form are disclosed for both intraoral and oral administration to a patient, said unit dosage form configured to be placed intraorally of said patient. The dosage form is as described in Figure 1, which comprises: (a) as a first portion, at least one discrete molded triturate tablet comprising a therapeutically effective amount of at least one pharmaceutically active ingredient capable of intraoral administration ; and (b) as a second portion located around the said first portion, a therapeutically effective amount of at least one p harmaceutically active ingredient capable of oral administration and which is releasable and orally ingestible by the patient after the molded triturate tablet has disintegrated or has dissolved intraorally.
PCT/US2002/038246 2001-11-30 2002-11-27 'compressed annular tablet with molded triturate tablet for oral and intraoral' WO2003047519A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002468558A CA2468558A1 (en) 2001-11-30 2002-11-27 "compressed annular tablet with molded triturate tablet for oral and intraoral"
EP02789933A EP1455759A2 (en) 2001-11-30 2002-11-27 Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
AU2002352973A AU2002352973B2 (en) 2001-11-30 2002-11-27 Compressed annular tablet with molded triturate tablet for oral and intraoral
JP2003548780A JP2005511647A (en) 2001-11-30 2002-11-27 Compressed annular tablets with oral and oral molded powder tablets

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/015,930 US6863901B2 (en) 2001-11-30 2001-11-30 Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
US10/015,930 2001-11-30

Publications (2)

Publication Number Publication Date
WO2003047519A2 WO2003047519A2 (en) 2003-06-12
WO2003047519A3 true WO2003047519A3 (en) 2004-04-08

Family

ID=21774402

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/038246 WO2003047519A2 (en) 2001-11-30 2002-11-27 'compressed annular tablet with molded triturate tablet for oral and intraoral'

Country Status (6)

Country Link
US (2) US6863901B2 (en)
EP (1) EP1455759A2 (en)
JP (1) JP2005511647A (en)
AU (1) AU2002352973B2 (en)
CA (1) CA2468558A1 (en)
WO (1) WO2003047519A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9320710B2 (en) 2006-01-06 2016-04-26 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
EP2295043A1 (en) 1999-10-29 2011-03-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US6476006B2 (en) * 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
CN101317825A (en) 2000-10-30 2008-12-10 欧罗赛铁克股份有限公司 Controlled release hydrocodone formulations
US6863901B2 (en) * 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
US6827946B2 (en) * 2001-12-05 2004-12-07 Collegium Pharmaceutical, Inc. Compositions containing both sedative and non-sedative antihistamines
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
NZ552514A (en) * 2001-12-24 2008-08-29 Teva Pharma Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
AU2003303631B2 (en) * 2002-12-26 2008-05-29 Nuvo Pharmaceuticals (Ireland) Designated Activity Company Multilayer Dosage Forms Containing NSAIDs and Triptans
US6881142B1 (en) * 2003-09-12 2005-04-19 Degree C Intelligent networked fan assisted tiles for adaptive thermal management of thermally sensitive rooms
GB0317904D0 (en) * 2003-07-31 2003-09-03 Jagotec Ag Improvements in or relating to organic compounds
US20050031688A1 (en) * 2003-08-04 2005-02-10 Ayala William J. Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
US20050142203A1 (en) * 2003-12-30 2005-06-30 Grant Heinicke Oral dosage formulations of active pharmaceutical ingredients and methods of preparing the same
ES2244324B1 (en) * 2004-03-25 2006-11-16 Ferrer Internacional, S.A. DIURETIC COMPOSITIONS OF PROLONGED RELEASE.
WO2006012634A1 (en) * 2004-07-26 2006-02-02 Teva Pharmaceutical Indudstries, Ltd. Dosage forms with an enterically coated core tablet
JP2008507587A (en) * 2004-07-26 2008-03-13 テバ ファーマシューティカル インダストリーズ リミティド Dosage form with enteric coated core tablet
US20070003622A1 (en) * 2004-12-16 2007-01-04 Sovereign Pharmaceuticals, Ltd. Diphenhydramine containing dosage form
US9592197B2 (en) * 2004-12-16 2017-03-14 Sovereign Pharmaceuticals, Llc Dosage form containing diphenhydramine and another drug
EP2295036A2 (en) * 2004-12-10 2011-03-16 Talima Therapeutics, Inc. Liquid compositions and methods for treating conditions of the nail unit
US7529255B2 (en) * 2005-04-21 2009-05-05 Microsoft Corporation Peer-to-peer multicasting using multiple transport protocols
JP2008536922A (en) * 2005-04-22 2008-09-11 テバ・ファーマシューティカルズ・ユーエスエー・インコーポレイテッド Olanzapine pharmaceutical orally disintegrating tablets
CA2612917A1 (en) * 2005-06-23 2007-01-04 Schering Corporation Rapidly absorbing oral formulations of pde5 inhibitors
CA2616416A1 (en) * 2005-09-09 2007-05-03 Labopharm, Inc. Trazodone composition for once a day adminisitiation
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US7811604B1 (en) 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
EA012998B1 (en) * 2005-11-18 2010-02-26 Глэксо Груп Лимитед Machine and method for pharmaceutical and pharmaceutical-like product assembly
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US9066847B2 (en) * 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US20070185145A1 (en) * 2006-02-03 2007-08-09 Royds Robert B Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
US20100179214A1 (en) * 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin trans isomers and isomeric mixtures and methods of using the same to treat sleep disorders
US20090042971A1 (en) * 2006-05-19 2009-02-12 Somaxon Pharmaceuticals, Inc. Method of using low-dose doxepin for the improvement of sleep
WO2007136845A2 (en) * 2006-05-19 2007-11-29 Somaxon Pharmaceuticals, Inc. Low-dose doxepin for treatment of sleep disorders in elderly patients
WO2007136741A2 (en) * 2006-05-19 2007-11-29 Somaxon Pharmaceuticals, Inc. N-desmethyl-doxepin and methods of using the same to treat sleep disorders
US20100179215A1 (en) * 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders
CA2687124A1 (en) * 2006-05-19 2007-12-13 Somaxon Pharmaceuticals, Inc. Low dose doxepin formulations, including buccal, sublingual and fastmelt formulations, and uses of the same to treat insomnia
JP2009537553A (en) 2006-05-19 2009-10-29 ソマクソン ファーマシューティカルズ インコーポレイテッド Use of low-dose doxepin to improve sleep
US20090042972A1 (en) * 2006-05-19 2009-02-12 Somaxon Pharmaceuticals, Inc. Methods of using low-dose doxepin for the improvement of sleep
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
CA2693992C (en) 2006-07-20 2017-01-31 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
WO2008085567A1 (en) * 2006-10-04 2008-07-17 Somaxon Pharmaceuticals, Inc. Methods of using low-dose doxepin for the improvement of sleep
US20100105614A1 (en) 2006-10-25 2010-04-29 Somaxon Pharmaceuticals, Inc. Ultra low dose doxepin and methods of using the same to treat sleep disorders
US8946200B2 (en) * 2006-11-02 2015-02-03 Southwest Research Institute Pharmaceutically active nanosuspensions
WO2008070795A2 (en) 2006-12-06 2008-06-12 Somaxon Pharmaceuticals, Inc. Combination therapy using low-dose doxepin for the improvement of sleep
US20080139654A1 (en) * 2006-12-09 2008-06-12 Eric Mott Soderling Acetaminophen compositions having minimized side effects including reduced hepatotoxicity
WO2008105920A1 (en) * 2007-02-28 2008-09-04 Collegium Pharmaceutical, Inc. Antihistamine combination
EP2123275A1 (en) * 2007-03-15 2009-11-25 Toyo Boseki Kabushiki Kaisha Process for production of buprenorphine pharmaceutical preparation to be applied to mouth mucosa
CA2721133C (en) 2007-04-13 2018-11-06 Somaxon Pharmaceuticals, Inc. Low-dose doxepin formulations and methods of making and using the same
US20090169633A1 (en) * 2007-12-31 2009-07-02 Ta-Ping Liao Oral particle including pseudoephedrine hydrochloride and cetirizine dihydrochloride
US8404850B2 (en) * 2008-03-13 2013-03-26 Southwest Research Institute Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors
WO2009126931A2 (en) 2008-04-11 2009-10-15 Xvasive, Inc. Combination therapy for bipolar disorder
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
US8722706B2 (en) * 2008-08-15 2014-05-13 Southwest Research Institute Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts
US8309134B2 (en) * 2008-10-03 2012-11-13 Southwest Research Institute Modified calcium phosphate nanoparticle formation
US20100124560A1 (en) * 2008-11-14 2010-05-20 Mcneil Ab Multi portion intra-oral dosage form and use thereof
US20100190739A1 (en) * 2008-12-15 2010-07-29 Fleming And Company, Pharmaceuticals Rapidly Dissolving Vitamin Formulation and Methods of Using the Same
EP2233134A1 (en) 2009-03-27 2010-09-29 McNeil AB Multi-portion intra-oral dosage form with organoleptic properties
US20100247586A1 (en) * 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
WO2010138439A1 (en) * 2009-05-28 2010-12-02 Aptapharma, Inc. Multiparticulate controlled-release selective serotonin reuptake inhibitor formulations
US20110097401A1 (en) * 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
US9028873B2 (en) * 2010-02-08 2015-05-12 Southwest Research Institute Nanoparticles for drug delivery to the central nervous system
US9271899B2 (en) * 2010-04-30 2016-03-01 Allovate, Llc Methods, articles and kits for allergic desensitization, via the oral mucosa
MX2012012991A (en) 2010-05-11 2012-11-30 Cima Labs Inc Alcoholres i stant metoprolol - containing extended - release oral dosage forms.
EP2387993B1 (en) * 2010-05-21 2012-11-07 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Orally disintegrating tablets of zolmitriptan and process for preparing the same
EA035045B1 (en) 2013-09-19 2020-04-21 АЛЛОВЕЙТ, ЭлЭлСи Toothpaste compositions for delivering allergens to oral mucosa
WO2015065547A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
WO2015102337A1 (en) * 2013-12-31 2015-07-09 주식회사 씨티씨바이오 Pharmaceutical composition containing clomipramine and preparation method therefor
WO2020225773A1 (en) 2019-05-07 2020-11-12 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
MX2022013029A (en) 2020-04-17 2023-01-16 Honeybrains Llc Compositions and methods for treating neuropsychiatric disorders.
CN117482057A (en) * 2023-11-30 2024-02-02 福安药业集团宁波天衡制药有限公司 Stable granisetron hydrochloride tablet and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229447A (en) * 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US6294199B1 (en) * 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2297599A (en) * 1940-09-28 1942-09-29 Squibb & Sons Inc Effervescent tablet
GB800973A (en) 1954-08-13 1958-09-03 Sterling Drug Inc Improvements in or relating to pills or tablets
US4004036A (en) * 1966-05-31 1977-01-18 Alberto Culver Company Effervescent molded triturate tablets
US3898323A (en) 1970-04-15 1975-08-05 Mirlin Corp Taste modifying composition
US3873727A (en) * 1971-06-01 1975-03-25 Parke Davis & Co Stabilization of molded sublingual nitroglycerin tablets
US4139589A (en) 1975-02-26 1979-02-13 Monique Beringer Process for the manufacture of a multi-zone tablet and tablet manufactured by this process
CA1163561A (en) 1979-11-06 1984-03-13 Cyril Boroda Preparation containing nitroglycerine and optionally other medicaments and preparation thereof
NL8100259A (en) 1980-01-21 1981-08-17 Wellcome Found COMBINATIONS OF KETONES WITH HETEROCYCLIC COMPOUNDS, PHAMACEUTICAL PREPARATIONS CONTAINING THEM, METHOD FOR PREPARING SUCH PREPARATIONS AND USE THEREOF IN MEDICINE.
US4552899A (en) 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4783465A (en) 1984-04-09 1988-11-08 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
GB8430346D0 (en) * 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
US4814181A (en) * 1987-09-03 1989-03-21 Alza Corporation Dosage form comprising fast agent delivery followed by slow agent delivery
US5082667A (en) * 1988-06-07 1992-01-21 Abbott Laboratories Solid pharmaceutical dosage in tablet triturate form and method of producing same
US5776493A (en) 1989-07-14 1998-07-07 Alza Corporation Oral osmotic device for delivery of nystatin with hydrogel driving member
US5021053A (en) 1989-07-14 1991-06-04 Alza Corporation Oral osmotic device with hydrogel driving member
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5064656A (en) * 1989-11-14 1991-11-12 Dr. Gergely & Co. Uncoated pharmaceutical reaction tablet
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
WO1992015332A1 (en) 1991-03-04 1992-09-17 Warner-Lambert Company Novel salts/ion pairs of non-steroidal anti-inflammatory drugs in various dosage forms
JP2771911B2 (en) 1991-08-09 1998-07-02 三菱電機株式会社 Car navigation system
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5248310A (en) 1992-03-27 1993-09-28 Alza Corporation Oral osmotic device with hydrogel driving member
US5512299A (en) 1992-03-30 1996-04-30 Alza Corporation Method of treating oral inflammatory disease
US5294433A (en) 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
US5512293A (en) 1992-07-23 1996-04-30 Alza Corporation Oral sustained release drug delivery device
ES2051658T3 (en) 1992-08-06 1998-06-16 Gergely Gerhard EFFERVESCENT TABLETS EASY TO MANAGE.
US5609884A (en) * 1992-08-31 1997-03-11 G. D. Searle & Co. Controlled release naproxen sodium plus naproxen combination tablet
JPH08501083A (en) 1992-09-03 1996-02-06 セプラコア インコーポレーテッド Use of norastemizole for the treatment of allergic diseases
US5314697A (en) 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
US5573776A (en) 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
US5368588A (en) 1993-02-26 1994-11-29 Bettinger; David S. Parenteral fluid medication reservoir pump
CA2161217A1 (en) 1993-04-30 1994-11-10 Carmelita Macklin Russell Coated pharmaceutical compositions
US5362496A (en) 1993-08-04 1994-11-08 Pharmetrix Corporation Method and therapeutic system for smoking cessation
US6183778B1 (en) 1993-09-21 2001-02-06 Jagotec Ag Pharmaceutical tablet capable of liberating one or more drugs at different release rates
US5407339A (en) 1993-09-27 1995-04-18 Vector Corporation Triturate tablet machine
US5451409A (en) 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
US5702723A (en) * 1994-08-02 1997-12-30 Griffin; David Multi-stage delivery system for ingestible medications or nutrients
US5827180A (en) 1994-11-07 1998-10-27 Lifemasters Supported Selfcare Method and apparatus for a personal health network
US5595997A (en) 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
US6379651B1 (en) * 1995-02-07 2002-04-30 Josman Laboratories Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases
US5656284A (en) 1995-04-24 1997-08-12 Balkin; Michael S. Oral transmucosal delivery tablet and method of making it
US5558879A (en) 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
US5807579A (en) 1995-11-16 1998-09-15 F.H. Faulding & Co. Limited Pseudoephedrine combination pharmaceutical compositions
US5648358A (en) 1996-03-05 1997-07-15 Mitra; Sekhar Compositions and methods for treating respiratory disorders
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
US5900421A (en) 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
DE19715594A1 (en) 1997-04-15 1998-10-22 Bayer Ag Analgesic combination
DE69818607T2 (en) 1997-05-30 2004-07-29 Osmotica Corp. MULTILAYER OSMOSIS DEVICE
IL133420A (en) 1997-08-26 2004-07-25 Aventis Pharma Inc Pharmaceutical composition in form of tablet comprising combination of antihistaminic piperidinoalkanol with decongestant sympathomimetic drug
US6166037A (en) 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
JP2001517626A (en) 1997-09-19 2001-10-09 ザ、プロクター、エンド、ギャンブル、カンパニー Compositions and methods for treating respiratory disorders
FR2772615B1 (en) 1997-12-23 2002-06-14 Lipha MULTILAYER TABLET FOR INSTANT RELEASE THEN PROLONGED ACTIVE SUBSTANCES
US6110500A (en) * 1998-03-25 2000-08-29 Temple University Coated tablet with long term parabolic and zero-order release kinetics
US6372254B1 (en) * 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
US6051585A (en) 1998-12-07 2000-04-18 Weinstein; Robert E. Single-dose antihistamine/decongestant formulations for treating rhinitis
US6086914A (en) 1999-03-12 2000-07-11 Weinstein; Robert E. Nonsedating formulations for allergic rhinitis which possess antihistaminic and anticholinergic activity
AR031068A1 (en) 1999-04-13 2003-09-10 Beecham Pharm Pte Ltd A PHARMACEUTICAL FORMULATION OF MODIFIED RELEASE THAT INCLUDES AMOXICILLIN AND POTASSIUM CLAVULANATE IN A RATIO OF 2: 1 TO 20: 1, A COMPRESSED IN LAYERS, THE USE OF AMOXYCLINE AND THE POTASSIUM CLAVULANATE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT COMPACT GRANULES
US6114346A (en) 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine
US6572891B1 (en) * 1999-10-23 2003-06-03 Alkaloid Ad Sublingual oral dosage form
WO2001037814A1 (en) 1999-11-23 2001-05-31 Robert Gordon University Bilayered buccal tablets comprising nicotine
AU2277301A (en) 1999-12-21 2001-07-03 Schering Corporation Treating allergic and inflammatory conditions
DE19963319C2 (en) 1999-12-21 2002-02-14 Hennig Arzneimittel Gmbh & Co Oral pharmaceutical preparation
US6602518B2 (en) * 2001-06-28 2003-08-05 Wm. Wrigley Jr. Company Chewable product including active ingredient
MXPA04000209A (en) * 2001-07-10 2005-03-07 Teva Pharma Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery.
US6863901B2 (en) * 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229447A (en) * 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US6294199B1 (en) * 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9320710B2 (en) 2006-01-06 2016-04-26 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain

Also Published As

Publication number Publication date
WO2003047519A2 (en) 2003-06-12
AU2002352973B2 (en) 2006-05-11
US7387792B2 (en) 2008-06-17
US20050123609A1 (en) 2005-06-09
US20030118648A1 (en) 2003-06-26
US6863901B2 (en) 2005-03-08
JP2005511647A (en) 2005-04-28
EP1455759A2 (en) 2004-09-15
CA2468558A1 (en) 2003-06-12
AU2002352973A1 (en) 2003-06-17

Similar Documents

Publication Publication Date Title
WO2003047519A3 (en) 'compressed annular tablet with molded triturate tablet for oral and intraoral'
WO2007009806A3 (en) Solid dosage formulations of narcotic drugs having improved buccal adsorption
WO2005046640A3 (en) Multi-site drug delivery platform
JP2005515966A5 (en)
WO2003066029A3 (en) Pharmaceutical dosage form for mucosal delivery
CA2389235A1 (en) Controlled release hydrocodone formulations
EP0966966A3 (en) Nefazodone dosage form
EP1674084A3 (en) Extended release oral dosage composition
HUP0302319A3 (en) Pharmaceutical composition for oral administration of active ingredient
MX9804008A (en) Pharmaceutical formulations.
TW200505498A (en) Sugar-free oral transmucosal solid dosage forms and uses thereof
CA2388610A1 (en) Oral transmucosal drug dosage using solid solution
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
CA2401569A1 (en) Low dose entecavir formulation and use
CO5170471A1 (en) MODIFIED RELEASE TABLETS INCLUDING AMOXYLIN AND POTASSIUM CLAVULANATE
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
WO2000078294A3 (en) Oral administration form for administering a fixed tramadol and diclofenac combination
WO2002024203A3 (en) Controlled release formulations for oral administration
IL159217A0 (en) An oral pharmaceutical formulation comprising a basic pharmaceutically active ingredient having ph-dependent solubility, a process for the manufacture thereof and use thereof in medicine
CA2411882A1 (en) Solid valsartan pharmaceutical compositions
IL158668A0 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
WO2002011694A3 (en) Compositions and dosage forms for application in the oral cavity in the treatment of mykoses
WO2005004860A3 (en) Novel solid pharmaceutical composition comprising amisulpride
IL179544A0 (en) Compositions comprising flavonoids and tocotrienols and methods thereof
CA2180178A1 (en) Use of 2,3-diaryl-1-benzopyran derivatives for the manufacture of a medicament in the treatment and prevention of bone loss and osteoporosis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2468558

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003548780

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002789933

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002352973

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2002789933

Country of ref document: EP